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The family of the mammalian small heat-shock proteins consists of 10
members (sHSPs/HSPBs: HSPB1–HSPB10) that all share a highly conserved
C-terminal alpha-crystallin domain, important for the modulation of both
their structural and functional properties. HSPB proteins are biochemically
classified as molecular chaperones and participate in protein quality control,
preventing the aggregation of unfolded or misfolded proteins and/or assist-
ing in their degradation. Thus, several members of the HSPB family have
been suggested to be protective in a number of neurodegenerative and neu-
romuscular diseases that are characterized by protein misfolding. However,
the pro-refolding, anti-aggregation or pro-degradative properties of the var-
ious members of the HSPB family differ largely, thereby influencing their
efficacy and protective functions. Such diversity depends on several factors,
including biochemical and physical properties of the unfolded/misfolded
client, the expression levels and the subcellular localization of both the cha-
perone and the client proteins. Furthermore, although some HSPB members
are inefficient at inhibiting protein aggregation, they can still exert neuropro-
tective effects by other, as yet unidentified, manners; e.g. by maintaining the
proper cellular redox state or/and by preventing the activation of the apop-
totic cascade. Here, we will focus our attention on how the differences in the
activities of the HSPB proteins can influence neurodegenerative and neuro-
muscular disorders characterized by accumulation of aggregate-prone
proteins. Understanding their mechanism of action may allow us to target
a specific member in a specific cell type/disease for therapeutic purposes.1. Introduction
The family of the mammalian small heat-shock proteins, also called the HSPB
proteins, consists of 10 members (HSPB1–HSPB10, see alternative names of
each member in table 1), all of a relatively low molecular weight (MW, ranging
from 15 to 45 kDa) and sharing some structural similarities, like a highly con-
served C-terminal alpha-crystallin domain (ACD, [52]). This ACD plays an
important role in the modulation of both structural and functional properties
of the HSPBs. Indeed, monomers of the HSPB proteins associate (partially via
their ACDs) into dimers that are thought to act as basic units/building blocks,
capable of generating oligomers ranging from ca 200 to 600 kDa [49,53]. The
various HSPB monomers can form both homo- and hetero-dimers as well as
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association/dissociation of the oligomers has been suggested
to be key to the function of the HSPB proteins and is often regu-
lated by their phosphorylation state [49,56]. HSPB proteins are
biochemically classified as molecular chaperones and partici-
pate in protein quality control; in fact, several HSPB family
members have been shown to be able to bind to (partially)
unfolded or to misfolded, aggregation-prone proteins [57] pre-
venting their aggregation. In conjunction with ATP-dependent
chaperones (e.g. HSP70s/HSPAs), the HSPB-bound clients can
either be refolded ordegraded; themechanisms for either refold-
ingor degradation is not fully understood, butmaydepend both
on the state of the client and on the specific HSPBmember that is
bound to it (see later).
The chaperone activity of small HSPs has been discovered
and explored mainly in cell-free experiments with purified
proteins [58–60] and it accounts for, for example, the role
that HSPB4 plays in maintaining eye transparency [26].
Whether this chaperone function is also underlying other cel-
lular functions of HSPB members is less clear. For example,
some HSPBs members (e.g. HSPB1 and HSPB5) have the
capability to modulate the assembly and stabilization of
cytoskeleton components, such as actin and intermediate fila-
ments [22,37,38,41,61–64], but how far these actions rely on
their chaperone activity is unknown. It is also not clear
whether other HSPB family members serve in cytoskeletal
protection or whether different cytoskeletal and contractile
elements may require different HSPB members. Other func-
tional endpoints that have been shown to be affected by
HSPB members include the maintenance of proper cellular
redox state, protecting cells from oxidative stress conditions
(HSPB1, [65]), a general anti-apoptotic function (HSPB1,
[66,67]) and a role in skeletal muscle cell differentiation
(HSPB2 and HSPB3, [25]). The biochemical mechanisms
underlying these different cellular effects of the various
HSPB members are often still elusive and not always directly
linked to the in vitro-defined chaperone-like activities.
Several HSPB family members have been suggested to be
protective in a number of neurodegenerative and neuromus-
cular diseases that are characterized by protein aggregation
and axonal transport defects. This directly relates back to
the two most postulated actions of these HSPBs: their chaper-
one action and cytoskeletal stabilizing function, respectively.
On the other hand, mutations in some members of the HSPB
family (namely, HSPB1, HSPB3, HSPB4, HSPB5 and HSPB8)
have been associated with neurological and muscular alter-
ations, suggesting that loss of their function as general
chaperones or/and cytoskeletal protectors is crucial for main-
taining neuronal and muscular cell function and viability.
Here, we will discuss the implication of HSPB proteins in
neurodegenerative and neuromuscular diseases, focusing
our attention on how the differences in the HSPB activities
influence their protective functions.2. The role of HSPBs in neurodegenerative and
neuromuscular diseases
(a) Some HSPBs are upregulated in
neurodegenerative diseases
The formation and accumulation of insoluble aggregates
containing misfolded/mutated proteins is a pathologicalhallmark of many neurodegenerative and neuromuscular dis-
orders with late onset, including amyotrophic lateral sclerosis
(ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD),
polyglutamine (polyQ) diseases (e.g. Huntington disease
(HD), spinal and bulbar muscular atrophy (SBMA), etc.),
and Creutzfeldt–Jacob disease (CJD). These diseases include
both sporadic and genetically inherited forms. Some inheri-
ted forms are linked to mutations in a specific protein that
misfolds and/or is prone to aggregation. Notably, often
the proteinaceous aggregates are found in the corresponding
degenerated tissues. Protein aggregation is a multi-step
nucleation-dependent process starting from the oligomerization
of the self-associating misfolded protein, which generates pre-
fibrillar aggregates (detergent-soluble). Pre-fibrillar aggregates
can subsequently generate fibrillar structures (detergent-inso-
luble). During this aggregation process, the mutated protein
interacts with and entraps different intracellular components.
These include several HSPs (including several HSPB mem-
bers; [68]), components of the proteasome system, elements
involved in vesicular transport and transcription factors.
Sequestration of HSPs and proteasomal components may
reflect their failure to degrade the misfolded proteins as well
as their failure to prevent their aggregation or their unsuccess-
ful attempts to disaggregate the inclusions. As a consequence,
the HSPs might be diverted away from their normal functions.
Similarly, entrapping of vesicular transport components and
transcription factors may lead to their reduced activities in
essential neuronal processes. Finally, aggregates might phys-
ically impair cellular processes (e.g. axonal transport) [69].
Probably, a combination of these events contributes to disease
progression and, therefore, aggregation has long been con-
sidered the key pathogenic mechanism. Nevertheless, the
precise role of aggregates in neuronal cell death and disease
progression is still largely debated. Several studies have
suggested that not all forms of aggregates may be toxic
[70–72]. In fact, large (amyloidic) aggregates that entrap
these various key cellular elements have been found to be
protective in certain systems and under certain conditions
[70–75]. It has thus been proposed that smaller (amorphic)
oligomeric and/or heteromeric species are more toxic as
they are capable of freely moving around in the cellular
milieu and perturb various neuronal functions. Besides the
aforementioned effects of large aggregates (e.g. impairment
of cellular proteostasis, alterations of the degradative systems,
disruption of axonal transport, dysregulation of the transcrip-
tion of specific genes), this could also include, for instance
direct effects on membrane integrity and/or synaptic func-
tioning [70,73,76,77]. However, irrespective of the presumed
differential toxicity attributed to these different aggregates,
it is clear that any factor/approach able to decrease mutated
protein accumulation, to prevent the initiation of their aggre-
gation or to facilitate the clearance of (early) aggregates will
greatly contribute to restore (or maintain) the normal neur-
onal proteostasis and function, thus slowing down disease
progression. This potentially can be achieved by boosting
specific molecular chaperones/HSPs (e.g. HSP70s/HSPAs
and HSP40s/DNAJs and some sHSPs/HSPBs), which will
avoid or attenuate protein aggregation, or by stimulating
the degradative pathways (i.e. autophagy), which will help
to clear the aggregates. The efficacy of both approaches has
been experimentally demonstrated using cellular and/or
animal models of aggregate diseases (e.g. polyQ diseases,
AD and PD) [19,43,46,78–91].
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proteins as a potential approach to counteract protein toxicity
in neurodegenerative diseases, keeping in mind that not all
HSPB family members share the same functional properties
[1,92]. Therefore, the putative protective efficacy of the
10 members may largely differ depending on the specific
protein causing the aggregation disease.
In addition, the various members present very different
tissue/cell-specific distribution. In basal conditions, only
some HSPB family members are expressed in the central ner-
vous system (CNS) and very few in neurons (some are mainly
confined in glial components of the CNS; table 1). However,
misfolded protein expression and the consequent cell stress
during neurodegeneration might trigger both the overexpres-
sion of some HSPBs already present in target cells or of
HSPBs normally silent in neurons (table 1). Thus even the
HSPBs normally absent in the brain might become players
in the intracellular response to mutant misfolded protein neu-
rotoxicity [92]. Regarding the specific pattern of expression of
the HSPB family members, HSPB2 and HSPB3 are mainly
expressed in the skeletal muscle cells [25], while HSPB9 and
HSPB10 are only found in testis [52]. HSPB7 was originally
termed cvHSP and indeed is highly expressed in cardiac
tissue, although it is also expressed at lower levels in several
other tissues, including the brain [1,92]. HSPB6 is constitu-
tively and highly expressed in smooth, cardiac and skeletal
muscles and plays a role in muscle function [93]. The other
members (HSPB1, HSPB5 and HSPB8) are highly expressed
in muscle tissues, but are also expressed in many other
tissues, including in the CNS, with peculiar cell-type-
dependent differences in expression (table 1). For example,
while HSPB1 is highly expressed in peripheral sensory
neurons [94], HSPB8 is highly expressed in motor neurons
[17,33,43,44,95]. As it will be discussed later, some members
of the HSPB family can prevent aggregation of (some) dis-
ease-associated mutant proteins and that is though to be
protective in neuronal cells. Thus, HSPB upregulation (both
at the level of neuronal and glial cells) might represent a pro-
tective cellular response to neuronal damage. However, it is
also possible that this over-induction occurs as a consequence
of neuronal stress, without an active participation to the pro-
tective processes. While the presence of HSPB1 and HSPB5 in
ballooned neurons (e.g. in AD, CJD, etc.) could suggest that
they interact with aggregates in neurons (either actively
engaged in protein quality control here or reflecting failed
function or being trapped here), the upregulation of the
same proteins in astrocytes is more difficult to understand.
But several lines of evidence suggest that misfolded proteins
may act in a non-cell autonomous way. For example, the pri-
mary toxicity can be exerted on the glial (and microglia) cells
surrounding affected neurons, which may thus also be
indirectly affected via release of neurotoxic factors from glia
or reduced removal of neurotoxic agents by the glia, i.e.
through an altered dialogue between these cells [96,97].
Indeed, recent evidence suggests that astrocytes, together
with other glial cells (especially microglia), participate in
the maintenance of the extracellular milieu containing
debris and aggregates from dying neurons. A comparable
non-cell autonomous mechanism may play a role in motor
neuron diseases, involving interactions between motor neur-
ons and the target muscle cells [98] in which muscle
denervation from motor neurons rather than being causative
to muscle degeneration also may result as consequence ofinitial muscle damage/death [99,100]. It can be hypothesized
that HSPB8, for example, somehow is involved in this pro-
cess: in anterior horn spinal cord of ALS mice, HSPB8 is
highly induced not only in motor neuron (at very high
levels in this primary target of mutant protein toxicity), but
also in the glial cells (at lower levels) of the affected regions
[43], and in muscle tissues (at the highest levels; P. Rusmini,
V. Crippa, E. Giorgetti, A. Boncoraglio, R. Cristofani, A.
Poletti 2013, unpublished data). Studies should therefore
not only focus on elucidating the role of HSPBs in individual
populations of cells, but also look at cell non-autonomous
and cell–cell interactions.
Finally, low or even a complete lack of constitutive and
induced expression in target cells of individual HSPBmembers
that did reveal protective power in cell models of disease
should not be a reason to imply that these members cannot
exert protective functions in disease. Obviously, suchmembers
are not part of the canonic intrinsic (neuronal/glial/muscular)
response to the diseased protein, but could be still considered
potential therapeutic targets if one were able to induce them
by pharmacological means, with the specific aim to assist
mutant neurotoxic protein clearance.3. Refolding and anti-aggregation are distinct
properties of the HSPBs
As previously mentioned, a number of neurodegenerative
diseases are characterized by the progressive accumulation
of aggregation-prone proteins. Upregulation of specific mem-
bers of the HSPB family could slow down or completely
inhibit the aggregation process in cell models [43,46–
48,92,95,101], with significant differences among the 10
HSPB family members. In particular, using mutated polyQ-
containing proteins (e.g. huntingtin and ataxin-3) we
showed that HSPB6, HSPB7, HSPB8 and HSPB9 overexpres-
sion inhibited protein aggregation and protected against its
mediated toxicity, while overexpression of all the other mem-
bers had no effect [1]. Curiously, HSPB6, HSPB7, HSPB8 and
HSPB9 could not efficiently facilitate the refolding of
denatured substrates (e.g. heat-denatured firefly luciferase),
but rather were linked to protein degradation by either the
proteasomal or the autophagic systems (table 1; see also
later, [1,46]). Inversely, the strongly heat-stress-regulated
HSPB1, HSPB4 and HSPB5 members, which were found to
be very efficient in facilitating the refolding of heat-denatured
substrates, both in cells and in vitro, showed poor anti-aggre-
gation effects against polyQ proteins (table 1) [1]. These data
suggest that the different HSPB members may either have
different client specificity and/or have a different impact on
client processing.
Despite the lack of anti-polyQ aggregation activity, HSPB1
andHSPB5 showed some protective effects in some cell models
of polyQ disease. As HSPB1 andHSPB5 can increase the resist-
ance of the cytoskeletal network [22,37,38,41,62–64] and are
upregulated both in ballooned neurons and astrocytes
[9,27,28], one may speculate that they protect axonal transport
and vesicular trafficking against disruption by the protein
aggregates and thus delay the consequences of aggregation,
without affecting aggregate formation as such. Yet, when
directly comparing the cytoprotective effects of, for example,
HSPB5 to that of HSPB7 in cell models, we found HSPB5
protection was marginal ([1], figure 1c).
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Figure 1. Comparison of effects of overexpression of HSPB5, HSPB7, HSPB8 and HSPB9 on the cellular capacity to refold heat-denatured luciferase (a) or to suppress
protein aggregation (b) and toxicity (c) of polyQ proteins in cells or to reduced polyQ-mediated eye degeneration in flies (d ). Data compiled and replotted from
[1,101] and (M. P. Zijlstra, B. Kanon, H. H. Kampinga 2011, unpublished data).
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pressors of polyQ aggregation (HSPB7, HSPB8 and HSPB9)
also reduced polyQ-mediated eye degeneration in a Drosophila
melanogaster in vivo model [1,101] (M. P. Zijlstra, B. Kanon,
H. H. Kampinga 2011, unpublished data; figure 1). These
latter three HSPB members have been implied in polyQ degra-
dation via the proteasome (HSPB9: M. P. Zijlstra, B. Kanon,
H. H. Kampinga 2011, unpublished data), by supporting
autophagic clearance of polyQ aggregates [1] or by enhancing
autophagic flux [43,46,95,101,102], see below).4. Anti-aggregation activity of HSPBs:
stimulating degradative pathways
As mentioned earlier, HSPB7, HSPB8 and HSPB9 seem to
have the potential to trigger (or facilitate) proteasomal and/
or autophagic degradation of certain misfolded proteins.
Among these HSPB members, HSPB8 is probably the most
studied in this context. Overexpression of HSPB8 efficiently
prevents aggregation of different polyQ-containing proteins
(huntingtin, ataxin-3 and androgen receptor (AR), responsible
for HD, spinocerebellar ataxia type 3 (SCA3) and SBMA,
respectively) [1,47,101], as well as SOD1 (protein responsi-
ble for ALS) and various truncated forms of TDP-43s
(associated with both ALS and frontotemporal dementia
(FTD; table 1)) [43,95].
Figure 2 illustrates this for the mutant ARpolyQ that causes
SBMA. Overexpression of HSPB8 in SBMA motor neurons
leads to a substantial decrease in mutant ARpolyQ aggregates
(IF, figure 2a) and large insoluble species (filter retardation
assay, FRA; figure 2b,c), which in this disease are triggered by
the AR ligand testosterone. Several data indicate that this
anti-aggregation activity of HSPB8 is caused by a facilitation
of autophagy-mediated degradation of the mutated proteins
or their (initial) aggregates. In this process, HSPB8 collaborates
with BAG3 [46] andHSPA8 (Hsc70) andCHIP [43,104]. Indeed,
as shown in figure 2, the anti-aggregation effects of HSPB8were
greatly reduced in the presence of the autophagy inhibitors
3-methyladenine (3-MA) or bafilomycin (figure 2c).
Differently from many other members of the HSPB family
(e.g. HSPB1 and HSPB7), HSPB8 forms a stable complex with
the HSPA8 (Hsc70) co-chaperone BAG3, which may explainwhy HSPB8 is so efficient in autophagy-mediated degradation
of misfolded polyQ substrates. We previously showed that not
only HSPB8 stability, but also its anti-aggregation and pro-
degradative functions, depend on its association with BAG3,
whose knock-down prevented HSPB8 from exerting its protec-
tive role [46]. Also, within the complex, BAG3, but not HSPB8,
is responsible for the stimulation of autophagy [46]. This
suggests that HSPB8 might play a role in the recognition and
delivery of the cargo, via BAG3, to the autophagosomes for
degradation. In addition, we found that HSPB8 (in complex
with BAG3), besides participating in autophagy-mediated
degradation of misfolded proteins, is also involved in the trans-
lational shut-downmediated by the induced phosphorylation of
eIF2 alpha that occurs during proteotoxic stress. Interestingly,
induction of phospho-eIF2 alpha,whichwe observeduponover-
expression of HSPB8, BAG3 or of the complex, leads to both
protein synthesis inhibition (which decreases the total load of
proteins to be refolded or degraded) and autophagy stimulation
(which clears the aggregated proteins accumulating during pro-
teotoxic stress) [48].While in vitro translation experiments indeed
have revealed that HSPB8 can cause translational shut-down,
precise insight into how HSPB8 can modulate translation upon
stress is still missing. Similarly, future studies will be needed to
reveal the precise role of HSPB8 in the complex and if and
how client recognition and targeting to autophagy is coupled
to its action on translation.5. The anti-aggregation power of HSPBs
depends on several factors
The aggregation propensity of misfolded proteins depends on
several factors, including the exposition of hydrophobic residues,
the alteration of specific conformed domains, the capability to
generate beta-plated sheets, and so on. These factors may affect
the kinetics of aggregation, the biophysical nature of aggregates
that are ultimately formed (e.g. insolubility and reversibility) and
also the location inside the cells where these proteins may
accumulate [105]. All of these may obviously also affect the pos-
sibilities of diverse HSPBs to interact and deal with these various
proteins before or after they have aggregated. Even for appar-
ently similar clients like the proteolytic polyQ-containing
fragments, the length of the polyQ stretch and the kinetics of
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Figure 2. (a) High-resolution fluorescence microscopy analysis of NSC34 cells transfected with GFP-AR.Q48 and an empty vector ( pCDNA3/untreated) or pCNEO-
cMyc-HSPB8 (expressing rat HSPB8). Cells were treated with 10 nM of testosterone (þT) for 48 h and fixed using a 1 : 1 solution of 4% saccharose and 4%
paraformaldeyde in 0.2 N PB (25 min at 378C under weak agitation), and then in ice-cold methanol (10 min, RT). Nuclei were stained with DAPI (dark grey,
blue). Images were obtained at 63 magnification. Fluorescence analysis showed that T-treated GFP-AR.Q48 formed intracellular aggregates that are completely
removed by HSPB8; a massive decrease of mutant ARpolyQ protein levels was also detectable, suggesting that HSPB8 induces the removal of mutant ARpolyQ from
immortalized motor neurons. Scale bar, 10 mM. (b) The effect of HSPB8 on the aggregation propensity of two AR mutants characterized by a polyQ of different
length was tested using filter retardation assay (FRA). NSC34 cells co-transfected with plasmids coding for AR.Q46 or AR.112 and either an empty vector ( pCDNA3)
or pCNEO-cMyc-HSPB8 (expressing rat HSPB8) were treated with ethanol (2T) or with 10 nM of testosterone (þT) for 48 h. Cell lysates were prepared for FRA as
previously described [86]. (c) The involvement of the autophagic pathway in the pro-degradative effects of HSPB8 on mutant AR.Q46 was tested by FRA after
selective blockage of the autophagic flux. NSC34 cells were co-transfected with plasmids coding for AR.Q46 and an empty vector ( pCDNA3) or pCNEO-cMyc-
HSPB8 (expressing rat HSPB8) and were treated with ethanol (2T) or with 10 nM of testosterone (þT) for 48 h. Autophagic flux was modulated using treatments
for 24 h with either 10 mM of 3-methyladenine (3-MA, acting on autophagosome assembly) or 10 nM of bafilomycin (BAF, acting on the process of fusion between
autophagosome and lysosome as well as on the ATP-dependent Hþ-pump [103]). Cell lysates used for FRA were prepared as previously described [86]. (Online
version in colour.)
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tion [1]) were found to impede the possibility of the various
HSPB members to suppress aggregation. While HSPB8 and
HSPB9 were equally (or even a bit more) effective compared
withHSPB7onhuntingtin fragmentswith relatively short expan-
sions (43Q, figure 1 [1]) only HSPB7 was efficient in suppressing
aggregation of the longest expansions tested (119Q; see [1]). For
HSPB8, similar observationsweremade in our previous findings
showing that HSPB8 efficiently decreases both soluble and inso-
luble levels of huntingtin fragments with relatively short
expansions (43Q; [46,47]), but has no effect on long expansions
(Q119; [1]).We also tested the selective effect of HSPB8 onARpo-
lyQ containing a stretch of different size (Q46 versus Q112), both
being in the pathological range (even if no SBMA patients with
Q112 have been described so far). The two types of ARpolyQshave a marked difference in their aggregation power, in
response to the AR ligand [72,73]. While HSPB8 almost com-
pletely counteracts AR.Q46 aggregation, induced by
testosterone, its effects on AR.Q112 are much lower, since
there is only a relatively small decrease in the total amount of
insoluble ARpolyQ (figure 2b).
These differences in the efficiency of HSPB7, on the one
hand, and HSPB8 and HSPB9, on the other hand, to prevent
aggregation of polyQ proteins with different expansion sizes
clearly suggests that their modes of action to deal with these
disease-related proteins must be largely different. HSPB8 and
also HSPB9 (M. P. Zijlstra, B. Kanon, H. H. Kampinga 2011,
unpublished data) seem to act by lowering the level of soluble
species (non-aggregated or/and early aggregate intermediates)
apparently maintaining these substrates in a state competent
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Figure 3. HSPB8 blocks the aggregation of several disease-associated mutant forms of TDP43. (a) HEK293 cells were transfected with vectors encoding for different
disease-associated mutant forms of TDP43 (DC, N352S, G348V or N345K, kindly provided by Dr E. Buratti) and either an empty vector or a vector encoding for
human HSPB8. Cellular lysates were prepared 72 h post-transfection and the aggregation of TDP43 mutants was analysed by FTA (as previously described; [43]).
(b) HEK293 cells were transfected with a vector encoding for DC TDP43 and either an empty vector or vectors encoding for various members of the HSPB family
(V5-HSPB1, V5-HSPB5, V5-HSPB6, V5-HSPB7 and V5-HSPB9). Aggregation of DC TDP43 was analysed as described in (a).
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insoluble species. In the case of HSPB8, the lowered levels of
soluble mutant polyQ proteins might be due, at least in part,
to its effects on eIF2 alpha phosphorylation and translational
attenuation [48]. Also, HSPB8, together with the co-chaperone
BAG3, the chaperone HSP70 and the ubiquitine-ligase
CHIP, works through stimulating autophagic degradation
[43,46,48,106], thus also taking care of early nucleating species.
Concerning HSPB9, it was found to stimulate proteasomal
degradation (M. P. Zijlstra, B. Kanon, H. H. Kampinga 2011,
unpublished data), which may lower the number of nucleating
species of the polyQ proteins; however, when nucleation is
initiated, which occurs more readily with longer polyQs,
HSPB9 might become ineffective. Since HSPB9 is only
expressed in testis, HSPB9 upregulation should not play a
role in neurodegenerative diseases. However, as stated
before, it is important to underline that pharmacologically
induced upregulation of specific members of the HSPB
family (normally not expressed or upregulated) in a specific
neuronal cell type might still result in protection, therefore
representing a good therapeutic approach. For those HSPB
members that are already expressed in target cells, drugs
may be designed that stimulate their (chaperone-like) activity,
e.g. by acting on the phosphorylation or oligomeric status of
the HSPB members. Alternatively, or in case HSPB members
are not already expressed in the target cells, analysis on
expression regulation of the various HSPBmembers combined
with drug screens using reporter constructs may identify
routes towards boosting or inducing expression of individual
disease-ameliorating members.
HSPB6, which only effectively suppresses shorter polyQs
[1,107], also plays a role in modulating autophagy [108]. By con-
trast,HSPB7doesnot change the rate ofproteasomaldegradation
and does not increases the autophagic flux; rather, it appears to
prevent early aggregates from nucleating into inclusions with
sizes that are too large to be handled by the autophagic machin-
ery, probably by marking these early seeds, which enables their
shuttling into the autophagosomes [1,57,109,110]. This HSPB7
action thus does not rely on the speed of seed formation but
rather on the rate at which these seeds grow (and thus is less
dependent on the size of the expansion).
Another aspect that might influence the efficacy of the
diverse HSPBs to prevent mutated protein aggregation is rep-
resented by specific physical properties of the mutant proteinand aggregate itself. Indeed, the effects of HSPB members on
different aggregation-causing mutants seem to differ widely
(table 1). It has been shown that, while polyQ proteins form
aggregates with a core that is inaccessible to nascent proteins,
mutated SOD1 (G85R/G93A), associated with ALS, forms a
porous aggregate, through which nascent proteins can diffuse
[110]. As stated above, we have already shown that overexpres-
sion of HSPB8 efficiently prevented the aggregation and
facilitated the autophagy-mediated degradation of mutated
SOD1 and of various mutated forms of TDP43, which is associ-
ated with both ALS and FTD [43] (figure 3a). When we
compared the HSPB8 activity to that of other HSPB family
members with anti-aggregation activity towards mutated
polyQ proteins, namely HSPB6, HSPB7 and HSPB9, none of
these blocked the aggregation of the truncated mutant form
of TDP43 (TDP43 DC; figure 3b: HSPB1-5-6-7-9; table 1).
HSPB1 and HSPB5, which mainly showed pro-refolding
activity, were also unable to prevent aggregation of TDP43
DC (figure 3b). HSPB9 seems to have a mild effect on TDP-43
DC. Why HSPB6 and HSPB7 showed no anti-aggregation
activity towards TDP43 DC, while being very active towards
mutated polyQ proteins [1,107] (table 1), is still unclear and
will be investigated in the future.
Finally, another factor that can explain the differential
efficacy of the various members of the HSPB proteins in
inhibiting protein aggregation is the stage at which they act.
As previously mentioned, many neurodegenerative diseases,
including AD, polyQ diseases and PD, are characterized
by the accumulation of fibrillar proteinaceous aggregates in
specific neuronal types [111–117]. The formation of these
fibrillar aggregates consists of a multi-step process involving
a nucleation step and the subsequent elongation of the fibrils
[118]. Interestingly, it has been shown that some HSPBs can
only prevent protein aggregation at a specific stage. For
example, HSPB5, which showed very high refolding capacity
in cells and in vitro but no anti-aggregation activity towards
mutated polyQ proteins [1], inhibits fibrillar aggregate for-
mation of mutated alpha-synuclein, associated with PD,
only at early stages. HSPB5 binds to partially folded mono-
mers of mutated alpha-synuclein, thereby preventing
mature fibril formation and shifting the equilibrium to
monomer fibrils, which can be easily disposed/degraded
[35,119,120]. A similar mechanism has been shown for
ataxin-3. HSPB5 can significantly inhibit the first stage of
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Josephin domain of ataxin-3, which has an intrinsic tendency
to aggregate and form fibrils [122]; however, HSPB5 is inef-
fective on already formed SDS-insoluble fibrils of mutated
ataxin-3. All together, these data strongly suggest that
HSPB5 acts as a chaperone specifically towards growing
fibrils at an early stage and may have only limited protective
powers because it cannot block protein aggregation at later
stages and does not seem to target its bound substrate to
the proteolytic pathways. They also suggest that, in order to
be efficient in inhibiting protein aggregation, upregulation
of HSPB5 should either take place at a very early stage of dis-
ease or occur concomitantly with the upregulation of other
chaperones able to bind to and target intermediate species
and/or fibrils to degradation.ocB
368:201104096. Subcellular localization of the aggregate-
prone species and HSPBs
Finally, subcellular localization can influence the efficiency of
the various members of the HSPB family in inhibiting the
aggregation of a specific misfolded substrate involved in neuro-
degenerative diseases. In fact, while the ubiquitin proteasome
system is present and active both in the nucleus and in the cyto-
plasm, autophagy (which can be facilitated by some HSPB
members; see earlier) is confined to the cytoplasm [123,124].
HSPB8 and HSPB6, which mainly rely on autophagy, are
expected to mainly act on cytoplasmic aggregating proteins.
Indeed, HSPB8 could only efficiently block the aggregation
and facilitate the autophagy-mediated clearance of ARQ46,
which is located in the cytosol, but had very limited effect on
ARQ112, which is aggregating inside the nucleus. Considering
that the cytoplasmic retention of amutated formofARcontain-
ing a Q112 tract ameliorates disease via autophagy [125],
strategies that allow keeping the mutated proteins in the cyto-
sol, where several HSPBs (and other molecular chaperones)
can participate directly or indirectly in their targeting to the
autophagosomes for degradation, will slow-down disease
progression. Whether some HSPBs can also participate in
modulating the shuttling of the mutated proteins from the
nucleus to the cytoplasm and whether this may contribute to
their protective effects is still unknown.7. HSPB-mediated protection can also be
independent of anti-aggregation/pro-
refolding activities and/or autophagy
facilitation
HSPB1, which shows good refolding capacity, had no anti-
aggregation activity in cells against mutated huntingtin,
both with short and long polyQ stretches [1] (table 1). How-
ever, overexpression of HSPB1 could inhibit the aggregation
of mutated SOD1 [20] (table 1) and could also prevent the
toxicity mediated by several polyQ-containing proteins [19].
This may depend on the different physical properties of the
aggregating substrates (e.g. immobile versus mobile aggre-
gates), as stated before, although so far no experimental
proof supporting such a hypothesis exists. However, in the
case of HSPB1, the protective effects may also be due to
other specific functions, which are not related to refoldingor inhibition of aggregation, but rather to its ability to prevent
the activation of APAF-1 by the cytochrome C released from
the mitochondria, that will trigger the apoptotic caspase
cascade, as well as on its anti-oxidants effects [67]. In fact,
overexpression of HSPB1 exerts a protective effect and signifi-
cantly decreases cell death in cellular models of HD,
characterized by high oxidative stress, by maintaining the
redox state of the cell without showing effects on aggregation
[19]. Moreover, in neuronal-like cells, HSPB1 could also pro-
tect against the toxicity mediated by mutated ataxin-3,
associated with SCA3, where increased oxidative stress has
been suggested to play a role in disease pathogenesis, again
without effects on aggregates. Interestingly, overexpression
of mutated ataxin-3 correlated with a reduction in the
expression levels of HSPB1, suggesting that a decrease in
the function of HSPB1 (not directly related to effects on the
diseased protein as such) may play a role in disease pro-
gression. Such a decrease in HSPB1 expression has also
been documented in other forms of SCA diseases, like
SCA7 [126,127] and in transgenic mice models of SCA-17
[128]. This would imply that re-introduction of HSPB1 can
compensate for such a loss of function of HSPB1 as a factor
contributing to disease progression. However, data in HD
mice did not reveal such an effect [129], suggesting that
this may not apply to all polyQ diseases.8. Conclusions and perspectives
Although similar in terms of primary sequence, the various
members of the mammalian HSPB family are differentially
expressed in tissues and cells, have different abilities to
form homo- and hetero-oligomers, show other non-HSPB
partner interactions and display different functions. The
tissue-selective expression pattern of the members probably
reflects a highly specific need of a given HSPB to assure
proper function and viability of that cell type/tissue, and a
particular HSPB may exert a protective function in a specific
cell type. Some functional redundancy does exist between the
various members, as evidenced by findings that several HSPB
members can handle the same (un- or misfolded) protein
equally (e.g. assist their (re)folding). However, HSPB members
posses different affinity and specificity for clients and may
handle the same client differently (e.g. routing them to protea-
somal or autophagosomal degradation). Thus, depending on
their client specificity and mechanism of action, only upre-
gulation of specific HSPB members would exert protective
functions against neurodegeneration. Moreover, impaired
HSPB function may harm certain tissues more than others
and explain why certain HSPB mutants have been linked to
tissue-specific (e.g. motor neurons and muscle cells) dege-
neration. In addition, the same HSPB may have different
biochemical activities: depending on their oligomeric status,
they may independently function as chaperones for soluble
proteins, as stabilizers/chaperones for cytoskeletal elements,
or as modifiers of the cellular redox state. As a consequence
of these properties, the same HSPB member may protect
more or less efficiently and certain HSPB members may be
better targets than others.
In general, a better understanding of the client specifi-
city and functional diversity of the various HSPBs will be
required in order to target a specific member or functionality
thereof for therapeutic purposes.
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